Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Clinical trial NCT06964737 · RECRUITING

Trial details

NCT number: NCT06964737
Sponsor: Ohio State University Comprehensive Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent Malignant Glioma Recurrent WHO Grade 3 Glioma Recurrent WHO Grade 4 Glioma WHO Grade 2 Glioma WHO Grade 3 Glioma WHO Grade 4 Glioma

Start date: 2025-05-21
Primary completion: 2027-05-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.